NCT01411657

NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Jeffrey L Goldberg · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple preclinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like ischemic optic neuropathy/optic nerve stroke. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in ischemic optic neuropathy. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.

Conditions

• Ischemic Optic Neuropathy/Optic Nerve Stroke

Interventions

Type	Name	Description
DRUG	NT-501 CNTF Implant	Single implantation of CNTF-secreting NT-501 device into one eye

Timeline

• Start date: 2011-04-01
• Primary completion: 2013-12-01
• Completion: 2014-10-01
• First posted: 2011-08-08
• Last updated: 2016-08-02

Locations

1 site across 1 country: United States